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Summary 
An interleukin 4 (Ib4)-specific monoclonal antibody (mAb) was administered to mice infected 
systemically with the yeast Candida albicans, and the animals were monitored for mortality, 
development of delayed-type  hypersensitivity, production of antibodies of different isotypes, release 
of II.-2, II.-4, Ib6, and interferon 3' (IFN-3') in vitro by splenic CD4 + lymphocytes, and levels 
of Ib4 and IFN-3' mRNA in these cells. Neutralization of IL-4 by three weekly injections of 
mAb in several independent experiments resulted in an overall cure rate of 81% versus 0% of 
controls. Cure was associated  with efficient  clearance  of the yeast from infected organs and histologic 
evidence  of disease resolution, detection of strong T helper type 1 (Thl) responses, and establishment 
of long-lasting  protective immunity. Soon after infection,  and as a result of the first or second 
injection of mAb, there was a decrease in Ib4 mRNA in CD4 + cells, which was accompanied 
by an increase in the levels of IFN-3'-specific transcripts. Our data thus indicate that the production 
of IL-4 by Th2 cells may limit Thl-associated  protective immunity in murine candidiasis. 
ecent evidence indicates that, early after exposure of mice, 
innate defense mechanisms are the primary means by 
which proliferation and growth of Candida albicans are held 
in check in the absence of underlying immunity, whereas 
later in the course of infection, clearance of the yeast is regu- 
lated, at least in part, by T cell-mediated immune responses 
(1). Long-term colonization  of adult mice in the absence of 
immunosuppressive  and  antimicrobial  treatment has been 
achieved by intragastric  colonization of infant (2) or germ- 
free (3) mice, or by systemic infection with attenuated yeast 
cells of  variant strains (4, 5). These studies have demonstrated 
that both specific cell-mediated immunity (6-8) and phago- 
cytic cell activity (4, 9, 10) are instrumental in the optimal 
expression of acquired anti-Candida resistance. In particular, 
in a systemic C. albicans infection model, evidence has been 
obtained that preferential production of  Thl or Th2 cytokines 
may underlie the development of protective vs. nonprotec- 
tive immunity, respectively,  as elicited by concomitant chronic 
infection with attenuated yeast cells (11). 
The role of cytokines in cutaneous lesions of murine leish- 
maniasis has been demonstrated by experiments in vivo, in 
which cytokine activities were blocked by administration of 
anticytokine mAbs. Anti-IFN-3' treatment of genetically resis- 
tant mice was found to result in development of progressive 
Leishmania major infection and detection of Th2 responses 
(12). In contrast,  anti-IL-4 treatment resuhed in cure of sus- 
ceptible mice, and the animals demonstrated Thl responses 
(13, 14). In general, these data are taken to indicate that IFN-3' 
and IL-4 are clearly involved in the process of subset differen- 
tiation of CD4 + T cells and may exert mutually inhibitory 
effects on both differentiation  and effector functions (14). 
Following our previous observations that anti-IFN-3' treat- 
ment in vivo will block the effector functions mediated by 
endogenous IFN-3" in immunized mice (7) and Th2 cells may 
be activated and functionally interact with Thl lymphocytes 
in candidal infections (11), we have investigated the effect of 
administration of anti-IL-4 mAb on antifungal resistance of 
systemically infected mice. Anti-IL-4 therapy initiated at the 
time of infection resulted in cure of a high percentage of mice 
with establishment  of protective  immunity. Cure was as- 
sociated with the detection of Thl responses, including strong 
delayed-type  footpad reactions and low serum IgE. There were 
also early and remarkable changes in Thl and Th2 cytokine 
production in vitro by CD4 + cells and cytokine mRNA ex- 
pression in these cells. 
Materials and Methods 
Mice.  Hybrid (BALB/cCr x  DBA/2Cr)F1 (CD2F  0 and in- 
bred BALB/c mice were obtained from Charles giver Breeding 
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age from 2 to 4 too, were used. 
Yeast and Infecn'ons.  The origin, characteristics,  and growth con- 
ditions of the highly pathogenic C. albicans (CA-6) strain used in 
this study have already been described in detail (6, 7). For infec- 
tion, yeast cells were harvested  by low-speed  centrifugation (1,000 
g), washed twice in PBS, and diluted to the desired density to be 
injected intravenously into mice in a volume of 500 #1. Quanti- 
fication of yeast cells in organs of infected mice was performed by 
a plate dilution method, using Sabouraud dextrose agar (6, 7), and 
results (means + SEM) were expressed as the number of CFU per 
organ. For histology, tissues  were fixed  in formalin, sectioned, and 
stained with periodic acid-Schi~s reagent or hematoxylin/eosin. 
Treatment of  Mice with ana'-IL,4 mA ~  The 11Bll hybridoma  line, 
producing rat IgG1 anti-IL-4 mAb (15), was grown as ascites in 
pristane-primed irradiated BALB/c mice, and the ascites fluid was 
passed over a desahing column (10DG; Bio-Red  Laboratories,  Rich- 
mond, CA) before antibody purification by means of affinity chro- 
matography with protein A-Sepharose CL-4B (Pharmacia, Upp- 
sala, Sweden). Protein concentration was determined by measuring 
the OD at 280 nm. Beginning 2 d before infection, mice received 
1 mg purified 11Bll mAb in 250 #1 PBS intraperitoneally once 
per week for 3 wk. Control mice received equivalent amounts of 
affinity-purified  rat IgG1 (Zymed  Laboratories, San Francisco,  CA). 
De/algal-type  Hy/xom~t/v/t  7 (/Y/H)' Assa?  A direct assay  system 
for measuring the DTH response to call surface antigens was em- 
ployed (6) in which heat-inactivated CA-6 cells (2  x  106/40 #1 
of pyrogen-free saline) were inoculated into the footpads of con- 
trol or yeast-infected  mice. The DTH reaction was recorded 24 h 
later by weighing the footpad as a measure of swelling, and the 
results were expressed as the increase  in footpad weight (right hind) 
over that of the saline-injected (left hind) counterpart.  Data are 
the means _+  SEM of six to eight mice per group. 
Selection of CD4 + Cells, Production of Culture Supernatants Con- 
mining Cytokine Activity, and Cytokine Assays.  CD4 + lymphocytes 
were positively selected from pools of spleen cells by means of a 
panning procedure using anti-murine CD4 mAb GK1.5, which 
resulted in a >95%  pure population on FACS  |  analysis (Becton 
Dickinson & Co., Mountain View, CA) (6, 7). Supernatants from 
mixed lymphocyte Candida cultures were obtained by culturing 
CD4 + lymphocytes in the presence of yeast cells and accessory 
macrophages (6, 11). Source and characteristics of the anticytokine 
antibody reagents used in IFN-% IL-2, IL-4, and Ib6 assays  were 
as described (6, 7,  11). Briefly, cell supernatants were tested for 
their concentration of  IFN-3, by two-site ELISA  using rat anti-mu- 
rine IFN-3/mAb K4-6A2 as the primary antibody and biotinylated 
monoclonal AN-18.17.24 as the secondary antibody. Ib2 and IL-4 
were measured using the HT2 T lymphocyte line that proliferates 
in response to either of these cytokines (16). mAbs $4B6 (anti- 
Ib2) and 11Bll (anti-Ib4),  at neutralizing concentrations, were 
used to establish monospecificity.  IL-6 activity was determined by 
its capacity to support the growth of the murine IL-6-dependent 
cell line 7TD1 (17). Proliferation  was assayed  using the tetrazolium- 
based colorimetric assay. All cytokine titers were expressed as units 
per milliliter,  calculated  by reference to standard curves constructed 
with known amounts of the recombinant cytokines (Genentech, 
Inc., South San Francisco, CA). 
Antibody Assay.  A micro-ELISA  procedure was used to quan- 
titate specific  antibodies in the sera of yeast-infected  mice (11). The 
assay involved coating the microtiter plate wells with heat-killed 
1 Abbreviation used in this loa~r: DTH, delayed-type  hypersensitivity. 
CA-6 cells, addition of appropriate dilutions of test antisera (from 
a pool of two to three mice per group), and a further reaction with 
alkaline phosphatase--conjugated rabbit  anti-mouse  IgG,  IgG1, 
IgG2a (Zymed Laboratories), or with biotinylated rat monoclonal 
anti-mouse IgE (Sanbio  by Biological  Products, Uden, The Nether- 
lands) followed  by an avidin-alkaline  phosphatase  conjugate (Vector 
Laboratories, Budingame, CA). After addition of the substrate so- 
lution, the OD of triplicate samples was read with an ELISA  reader, 
using a 405-nm filter. 
RNA Preparation andPCR.  CD4 + lymphocytes,  >95% pure, 
were obtained from spleen cells pooled from two to three animals, 
and 2  x  107 calls were subjected to  KNA extraction by the 
guanidium thiocyanate-phenol-chloroform  procedure (18). Ampli- 
fication of synthesized cDNA from each sample was carried out 
as reported (19), using 5' sense primers and 3' antisense primers 
from Clontech Laboratories  (Palo Alto, CA). Briefly,  5 #1 ofcDNA 
was added to a reaction mixture containing 50 mM KC1, 10 mM 
Tris-HCl (pH  8.3), 3.0 mM MgCh,  0.01% gelatin,  0.2  mM 
deoxynucleoside  triphosphates, 1 #M of each primer, and 2.5 U 
AmpliTaq polymer  ase (Perkin-Elmer Corp., Hayward, CA). Each 
100-#1 sample was overlayed  with 75 #1 mineral oil (Sigma Chem- 
ical Co., St. Louis, MO) and incubated in a DNA thermal cycler 
(480; Perkin-Elmer Corp.) for a total of 40 cycles, each cycle con- 
sisting of 1 rain at 94~  1 rain at 60~  (/~-actin and IFN-'y) or 
67~  (IL-4), and 1 min at 72~  The amplified  DNA size, as com- 
pared with a positive control (Clontech Laboratories), was 540 bp 
for 3-actin, 399 bp for IL-4, and 460 bp for IFN-% The PCR frag- 
ments were analyzed  by 1.5% agarose  gelelectrophoresis  and visual- 
ized by ethidium bromide staining. 
Results 
Effect o/In Vivo Neutralization of lL4 on the Course of Inocu- 
lation Candidiasis.  In six independent experiments, CD2F1 
mice received three weekly injections of anti-Ib4 (11Bll) or 
control antibodies starting 2 d before intravenous challenge 
with different numbers (5-50  x  104) of CA-6 blastospores. 
While aU control mice developed progressive,  disseminated 
fatal candidiasis  with median survival  times of 5-18 d de- 
pending on challenge dose, the overall survival rate of anti- 
IL-4-treated mice (totalling 54) was 81%. The results of three 
representative experiments are summarized in Table 1. In ex- 
periments not reported here, we also found that the beneficial 
effects of IL-4 depletion were essentiaUy lost when the size 
of the challenge inoculum was such (e.g.,  106 cells or more) 
as to result in animals' death within the first 24-96 h of in- 
fection. However, once cured by anti-Ib4 treatment, survivor 
mice would consistently resist challenge with 106 CA-6 ceils 
as performed 12 wk after primary infection (Table  1). 
Quantitative cultures of kidneys and brains from control 
and anti-IL-4-treated mice were established  6 h and 1, 2, or 
3 wk after injection of 7.5  x  104 CA-6 cells. Fig.  1 sum- 
marizes the results of one experiment representative  of three, 
and shows that mAb treatment was associated with a dra- 
matic reduction in fungal load in the organs of infected mice. 
At 3 wk, when no survivors were found in the control group 
(median survival time of 14.5 d), mice on anti-II~4  therapy 
had almost completely deared yeast cells from their organs. 
Examination of the kidneys from these mice provided histo- 
logic evidence  of disease resolution (Fig.  2). 
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to Inoculation Candidiasis 
Challenge dose  Treatment  MST  D/T 
d 
5  x  10  s  None  5.5  8/8 
5  x  10  s  Rat IgG1  5.5  8/8 
5  x  10  s  mAb  11Bll  >60  3/9" 
10  s  None  10  8/8 
10  s  Rat IgG1  10  10/10 
10  s  mAb 11Bll  >60  2/10 
5  x  104  None  16.5  8/8 
5  x  104  Rat IgG1  15  8/8 
5  x  104  mAb  llBll  >60  0/8" 
Mice challenged  with various  doses  of CA-6 cells  received  anti-IL-4  (11Bll) 
or control (rat IgG1) treatment. Median  survival times (MST) and num- 
ber of dead mice at 60 d over total animals  tested (D/T) were recorded. 
* Survivors resisted subsequent challenge  with 106 yeast cells (see text). 
Effect  of Anti-IL,4  Treatment  on  Footpad  Reaction  to  the 
Yeast.  To assess the possible effect of anti-IL-4 treatment on 
development  of DTH,  mice challenged with  7.5  x  104 
CA-6 cells, and treated with control or 11_811 antibodies, were 
injected intra-footpad with heat-inactivated blastospores 1, 
2, or 3 wk after infection. The increase in footpad weight 
was measured 24 h later (Fig. 3 A). Only mice receiving anti- 
Ib4  therapy  and  surviving  CA-6  challenge  developed 
significant footpad responses to the yeast. In addition, purified 
CD4 +  lymphocytes  from  cured  mice  could  adoptively 
transfer DTH reactivity to naive mice challenged intra-footpad 
with CA-6 cells 24 h after lymphocyte transfer (Fig.  3 B). 
Upon systemic challenge with viable CA-6, enhanced dear- 
ance of the yeast from infected organs could be documented 
in the adoptively transferred mice (data not shown). 
Effect of  Anti-IL,4 Treatment on Serum Levels of Candida-specific 
Antibodies.  We next measured the levels of yeast-specific an- 
tibody levels in sera of mice infected with C. albicans and treated 
with control or 11B1 antibodies. At 1, 2, and 3 wk after in- 
jection of 7.5  x  104 CA-6 cells, sera were collected and as- 
sayed for their contents of total IgG, Ig2a, IgG1, and IgE. 
Fig. 4 shows that, in the 2 wk preceding their death, control 
mice exhibited higher IgG1 levels and lower IgG2a levels in 
comparison with Ib4-depleted animals. Significant levels of 
IgE were also found. However, anti-Ib4 treatment of infected 
mice resulted in complete suppression of IgE production. 
Effect of Anti-Ib4  Treatment  on  Cytokine  Production In 
Vitro  To assess the effect of Ib4 depletion on cytokine re- 
lease in vitro by purified CD4 § lymphocytes from infected 
mice, mixed lymphocyte yeast cell cultures were established 
in the presence of accessory cells at 1, 2, and 3 wk after injec- 
tion of 7.5  x  104 CA-6 cells. Appropriate controls included 
CD4 +  cells  from  intact  donors  and yeast-primed CD4 + 
lymphocytes cultured with accessory cells but no fungal an- 
6. 
￿9  "  5"  f~ 
0 
4. 
O. 
o 
g  2. 
.-I 
1. 
~',  I  I 
6h  1  2  3  wk 
Figure 1.  Kecovery  of CFU from kidneys  (e) and brain (A) of CA-6- 
infected mice treated with anti-IL-4 (dashed lines) or control (solid lines) 
antibodies. The assay  was performed  at 6 h and 1, 2, or 3 wk postinfec- 
tion. Values are the mean of _+ SEM for eight mice per group (six for 
control mice at 2 wk). 
tigen. After 24 h of incubation, culture supernatants were 
assayed for their contents of IFN-% IL-2, IL-4, and II.-6. Fig. 
5 shows that anti-lD4 treatment resulted in enhanced produc- 
tion ofThl cytokines throughout the 3-wk observation period. 
In contrast, mice treated with control antibodies predomi- 
nantly produced IL-4 and I1.-6 during the 2 wk preceding 
their death. 
Expression of  lIM and lFN-  7 Genes in IL.4-depleted Mice.  To 
examine the patterns of cytokine gene transcription in Ib4- 
depleted mice, we extracted total RNA from CD4 + cells re- 
covered at different times after infection, reverse transcribed 
the polyadenylated mRNA to obtain cDNA, and detected 
cDNA by PCR with IL-4- and IFN-'y-specific primers. PCR 
products were verified by probing samples  transferred to a 
nylon membrane with a 32p-labeled internal oligonucleotide. 
To provide meaningful comparisons between control and IL- 
4-depleted mice, the cDNA samples were normalized to the 
~/-actin PCR product, a marker for all cells. Fig. 6 shows 
the results obtained with RNA preparations from two inde- 
pendent experiments, each involving challenge of  control and 
anti-Ib4-treated mice with 7.5  x  104 yeast cells, and har- 
vest of CD4 + lymphocytes 3 and 10 d after infection. Al- 
though the PCR products were not quantitated, the results 
apparently indicate that decreased  IL-4 mRNA levels were 
present in Ib4-depleted mice starting from 3 d postinfection, 
the decrease representing a manifold difference on day 10 (after 
the second mAb injection). A reciprocal  increase in IFN-y- 
specific transcripts was apparently observed as a result of Ib4 
depletion,  with substantially higher levels of message on 
day 10. 
Discussion 
Although superficial and systemic mycoses in humans are 
associated with different predisposing conditions (20),  one 
21  Romani  et al. Figure 2.  Effect of anti-IL-4 treatment  on renal candidiasis. Tissue sections were prepared from the kidneys (largest transverse diameter) of 3-wk- 
infected mice treated with weekly injections of I1Bll mAb (A). For comparison,  kidneys were also examined from control mice at the time of death 
(B). (A) An inflammatory  area in the cortex (delimited by arrows), but no evidence of fungal growth (hematoxylin/eosin;  x 75). (Inset)  Magnification 
of a lesion with a predominantly  lymphomononudear infiltrate (x 340). (B) Large aggregates of fungal yeasts and hyphae in the pdvis (arrows), abscesses, 
areas of dense leukocydc filtration, and papillary necrosis (x 70). (Insert) Numerous inflammatory leukocytes with filamentous forms of the fungus (x 140). 
feature common to all forms of candidiasis is that the intrinsic 
candidacidal  activity of granulocytes and macrophages (the 
major effector cell types) is rather limited (1), and that full 
expression of their function is contingent upon augmenta- 
tion by cytokines released by antigen-specific and nonspecific 
cells (21, 22). In addition, both specific  and nonspecific modu- 
lation of immune responses have been reported as a conse- 
quence of C.  albicans infection in mice. Garner et al.  (23) 
showed that mannan administered intravenously to naive mice 
induced a population of suppressor T lymphocytes  that, when 
transferred  to immunized mice, suppressed antigen-specific 
DTH responses. Ashman (24) suggested that active down- 
regulation of protective immunity might occur in mice that 
are genetically susceptible  to candidiasis  and are character- 
ized by high antibody levels and poor DTH responses. Our 
laboratory has recently found that activation of  Th2 cells occurs 
in mice infected with variants of the yeast that establish per- 
sistent colonization yet do not elicit  protective immunity, 
and CD4 §  cells from these mice were found to suppress 
Candida-specific  DTH responses  (11). 
In the present study we administered an anti-Ib4 mAb 
during the course of an otherwise lethal infection with the 
yeast. Provided the challenge inoculum did not result in short- 
term mortality, a vast  majority ('~80%)  of the anti-Ib4- 
treated mice began to actively eliminate yeast cells from their 
organs, resolved their infections,  and demonstrated Thl re- 
sponses. In contrast, mice treated with control antibody ex- 
perienced progressive, disseminated fatal candidiasis, and were 
characterized by weak or absent footpad responses, and higher 
IgG and IgE levels. The protective effect of anti-Ib4 treat- 
ment required the antibody to be given within approximately 
the first 2-3 d after infection, under which conditions a single 
antibody injection was almost as effective as the weekly ad- 
ministration regimen employed  in this study (Romani et al., 
manuscript  in  preparation).  Splenic  CD4 +  lympbocytes 
from infected and IL-4-depleted mice harvested at 1, 2, and 
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Figure 3.  DTH in yeast-infected mice treated with anti-Ib4 mAb (.4) 
or in mice adoptively transferred with CD4 + lymphocytes from  these 
animals (B). (A) At different times after CA-6 challenge, mice receiving 
111311 (t~) or control (I) antibodies were injected intra-footpad with in- 
activated yeast cells 24 h before measurement of their footpad response. 
As a negative control, uninfected mice (c) were assayed. (B) Prospective 
recipients of an intra-footpad  yeast challenge received an intravenous in- 
jection of 107 CD4 + lymphocytes from 2-wk-infected mice treated with 
11Bll  (D) or control ([]) antibodies. CD4 + cells from intact mice (c) 
were also transferred.  *Significant difference (/, <  0.01) from value ob- 
tained in control mice (c), as determined by Student's  t test.  Essentially 
the same results were obtained in two additional  experiments. 
3 wk postinfection  produced high IFN-'y and Ib2 levels, 
and substantially  reduced amounts of Th2 cytokines,  IL-4, 
and II.-6. At 3 and 10 d postinf~tion, CD4 + ceils from mice 
treated with anti-IL-4 mAb exhibited reciprocal changes in 
IL-4 and IFN-'y mRNA expression that represented mani- 
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Figure 5.  Thl and Th2 cytokine production in yeast-infected  mice treated 
with 11Bll (In) or control ([]) antibodies. Mixed CD4 + lymphocyte 
yeast cell cultures were established at 1, 2, and 3 wk postinfection,  and 
supernatants were assayed for IFN-% IL-2, IL-4, and IL-6 contents. Each 
value represents the mean _+  SEM of four to six separate experiments, 
each involving replicate measurements. Cytokine production in control 
cultures  (see text) was consistently negligible. 
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Figure 4.  Serum lg levels  in yeast-infected mice treated with 111311 (I) 
or control (D) antibodies. At 1, 2, and 3 wk after injection of 7.5  x 
10  4 CA-6 blastospores, sera were assayed for total IgG or IgG2a, IgG1, 
and IgE titers. Values represent the means  _+ SEM of three experiments. 
Specific antibody levels  in uninfected mice were negligible or undetectable. 
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Figure 6.  Ib4 and IFN-y mRNA expression in CD4 + cells revealed 
by PCK normalized to fl-actin. RNA was isolated from lymphocytes of 
control (C) or 11Bll mAb-treated mice at 3 and 10 d after infection, and 
the resulting eDNA was used in the PCK with cytokine-specific  primers. 
After amplification, 10/~1 of the reaction mix was removed, analyzed by 
1.5%  agarose gel electrophoresis, and visualized by ethidium bromide 
staining. The assay  was performed with two different RNA preparations, 
and a second assay  with the same RNA preparatiom gave analogous results. 
m, marker track (kilobase ladder consisting of pBR322 DNA cut with 
HaelII); N, no DNA added to the amplification mix during PCR. fold differences with respect to control lymphocytes on day 
10 postinfection. 
In murine cutaneous leishmaniasis,  the early and perma- 
nent conversion of nonhealer into healer mice induced by anti- 
I1-4 treatment (13, 25),  and the reversion  of the effect by 
anti-IFN-3, (14), indicates that the alteration of the disease 
outcome is primarily the consequence of changes in the basic 
nature of the T cell response,  with a shift from a predomi- 
nant Th2 to a Thl response.  A similar mechanism of anti- 
I1.4 activity might apply to mouse infection with C. albicans, 
although in the present study we have not examined the role 
of T cell-derived IFN-3, in the efficacy of anti-I1.4 therapy. 
The striking difference in I1.4 mRNA observed at 10 d could 
indicate that I1.4 depletion leads to blockade of Th2 cell ex- 
pansion. Because I1.4 is required for maturation of CD4 + 
precursors to the Th2 phenotype, neutralization of this factor 
would be expected to block both Th2 expansion and the sub- 
sequent formation of Th2-derived factors,  such as I1.4  and 
I1.10,  that limit protective Thl responses  (14, 26).  In addi- 
tion, the increase in IFN-y mRNA might indicate, and favor, 
the development of Thl reactivity, as IFN-y is crucially in- 
volved in the initial phases of Th responses in vivo (27). Fi- 
nally, neutralization of I1.-4 could further benefit the infected 
host by blocking the adverse effects of I1.4 on macrophage 
activation (28)  and killing of phagocytosed yeast cells. 
Elevated IgE, IgA, and IgG responses  to the yeast show 
an inverse relationship with delayed skin responses in atopics 
(29),  in women suffering from recurrent Candida vaginitis 
(20, 30),  and in patients with chronic mucocutaneous can- 
didiasis (20).  This suggests that humoral and cell-mediated 
immune responses to Candida in humans may be reciprocally 
regulated. Our present data that neutralization of endoge- 
nous I1.4  has therapeutic value in a murine model of sys- 
temic candidiasis could provide a means for improving our 
understanding of the host/parasite relationship, and also could 
offer the basis for attempting new strategies in the treatment 
of human candidiasis. 
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